Effect of Combination of Jian Gan Jiang Zhi Pill with Interferon in Chronic Hepatitis B Patients Associated with Nonalcoholic Fatty Liver Disease
10.3969/j.issn.0253-9896.2014.06.028
- VernacularTitle:健肝降脂丸联合干扰素治疗慢性乙型肝炎合并非酒精性脂肪肝的疗效观察
- Author:
Yuxiang HAN
;
Guowang LIU
;
Jing QIAN
;
Yili DUAN
- Publication Type:Journal Article
- Keywords:
hepatitis B,chronic;
fatty liver;
nonalcoholic fatty liver disease;
Jiangan Jiangzhi Pill
- From:
Tianjin Medical Journal
2014;(6):610-612
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the clinical features of HbeAg-negative chronic hepatitis B patients associate with non-alcoholic fatty liver disease (NAFLD), to value the effect of combining treatment on fatty liver influence and antivi-ral therapy. Methods Nighty eight chronic hepatitis B patients with non-alcoholic fatty liver disease (NAFLD) (Liver pa-thology G≥2 or S≥2,HBV DNA>1 × 105 copies/mL), were observed and given antiviral therapy with interferon alpha 1 b for 24 weeks. These patients were divided into combined treatment group (55 cases treated with interferon alpha 1 b combined with Jian Gan Jiang Zhi pills) and control group (43 cases treated with interferon alpha 1 b) in accordance with random num-ber table. All these patients took Leucoson to prevent blood cells reduction. The combined treatment effect was analyzed by observing and comparing biochemical serum change and HBV DNA negative conversion ratio between two groups. Re-sults After 24 weeks of antiviral therapy in Chronic hepatitis B patients with negative HBeAg associated with NAFLD, ALT and AST decreased significantly in both treatment group and control group. And this change is more obvious in treat-ment group than in control group. TC and TG in treatment group and TC in control group were also dropped with treatment (P<0.05). There is significant difference on HBV DNA negative conversion ratio between treatment groupand control group (98.2%vs 86.0%,P<0.05). Conclusion The combination of antiviral treatment and anti fatty liver treatment can obviously improve liver function and blood lipids, increase negative conversion ratio of HBV DNA for chronic hepatitis B patients asso-ciated with NAFLD.
